ArticleBrain and behavior2025
The Research of Proteomics in Neurodegenerative Diseases Based on Bibliometric Analysis.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Research of Proteomics in Neurodegenerative Diseases Based on Bibliometric Analysis.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis study aims to provide a comprehensive bibliometric analysis of the literature on proteomics in neurodegenerative diseases in order to identify research trends, key contributors, and collaborative networks and to assess the field's development and potential future directions.
methodA bibliometric analysis was conducted using data from 3461 publications (articles and reviews) published between 2000 and 2024, retrieved from the Web of Science Core Collection (WoSCC) database. The data were analyzed using CiteSpace, VOSviewer, and the R package "bibliometrix" to analyze and visualize publication trends, international and institutional collaborations, influential authors, and research focus areas. FINDING: This study uses bibliometric tools to visualize literature trends and collaborations. Analyzing 3461 publications from 2000 to 2024 shows a rise in publications, especially in the last 5 years, highlighting proteomics' importance in understanding diseases and finding therapies. The United States leads with 40% of publications, followed by China and Germany, with key institutions and authors identified.
conclusionDespite bibliometric analysis limitations, our findings emphasize proteomics' role in neurodegenerative research, suggesting future studies should use diverse data sources for a comprehensive understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.